Interview with Maurizio De Cicco, General Manager, Roche Italy
Roche Italy is one of the companies which went through the most significant re-organization process in the country in the past three years- with important changes in both its marketing…
Address: Via G.B. Stucchi 110, IT-20052 Monza (Milano),Italy
Tel: +39-039-2471
Web: http://www.roche.it/portal/roche-italia/home
Roche has been present in Italy since 1897, the subsidiary now employs about 1900 over the country. Its turnover in 2007 was over 928 million euros in the pharmaceutical market and 387 million euros in the diagnostic. Its plant is located in Segrate, about 10km from Milan, currently has about 400 employees and can cover all areas from production to packaging.Currently Roche clinical research in Italy takes part in about thirty experimental projects related to different therapeutic areas and involving over 30 researchers Roche and multiple partners among centers and universities and hospitals distributed throughout the country.
Roche Italy is one of the companies which went through the most significant re-organization process in the country in the past three years- with important changes in both its marketing…
Following the successful result of the “Piano Sanitario Nazionale” 2005 – 2008, could you introduce to ours readers the key priorities and main health policies to be implemented by 2009…
Following 20 years of a comprehensive experience in diverse fields of the pharmaceutical industry, you entered Baxter in 2000. At the time, the Italian affiliate was already a well established…
Despite Italy being one of the most important pharmaceutical markets not only in Europe but also in the World, the industry remained quite stable for the last two years and…
Grunenthal-Formenti relies on Formenti’s 60 years experience in Italy and is the result of the merger of both the German and Italian entities in 96. How would you describe the…
Having led a 26 years long career in Pfizer, you have been involved in a number of different countries including leading markets such as the US and Japan, but also…
You have worked in other countries such as the UK and the US with very large and significant pharmaceutical industries. What would you say is particular about the Italian pharmaceutical…
Since 1982, CNR has been the Italian public body which most contributed to the creation of inventions and innovations. What have been the main strategies behind such a success in…
Over more than 25 years, PAREXEL has expanded its global footprint through a combination of organic growth, alliances, and acquisitions. What was the rationale behind entering Italy in 1995 and…
Roche Italy is one of the companies which went through the most significant re-organization process in the country in the past three years- with important changes in both its marketing…
When you were appointed General Director of the Agenzia Italiana del Farmaco (AIFA) in 2007, the dedicated Investigation Commission highlighted the need for an in-depth reorganization of the Agency in…
When you became President of Sankyo Pharma Italy in 2003 one of your objectives was to maximize sales of the existing portfolio- and the company’s sales have impressively tripled in…
Intermediate distribution plays a crucial role in establishing bridges between industrial production and final delivery to patients- and in Italy, this function is executed with highly contained costs and commercial…
See our Cookie Privacy Policy Here
